(Q77535798)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9809887%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

review article

1 reference

title

Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9809887%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference

1 reference

S M Bates

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9809887%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

J I Weitz

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9809887%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

publication date

1 October 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9809887%20AND%20SRC:MED&resulttype=core&format=json

American Journal of Cardiology

6 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9809887%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

82

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9809887%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

issue

8B

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9809887%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

12P-18P

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9809887%20AND%20SRC:MED&resulttype=core&format=json

Are we mortgaging the medical profession?

6 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

The pathogenesis of coronary artery disease and the acute coronary syndromes (2).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Coronary plaque disruption.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Molecular and cellular biology of blood coagulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Plasmin-mediated activation of contact system in response to pharmacological thrombolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Low-molecular-weight heparins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Protection of factor Xa from neutralization by the heparin-antithrombin complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Human alpha-thrombin binding to nonpolymerized fibrin-Sepharose: evidence for an anionic binding region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Inhibited thrombins. Interactions with fibrinogen and fibrin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Binding of fibrin monomer and heparin to thrombin in a ternary complex alters the environment of the thrombin catalytic site, reduces affinity for hirudin, and inhibits cleavage of fibrinogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

A player of many parts: the spotlight falls on thrombin's structure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

The structure of a complex of recombinant hirudin and human alpha-thrombin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Kinetic mechanism for the interaction of Hirulog with thrombin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Synthetic low-molecular weight thrombin inhibitors: molecular design and pharmacological profile

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Thrombin active site inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl++ +) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Design and synthesis of potent and highly selective thrombin inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Highly selective tripeptide thrombin inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Clinical pharmacology of intravenously administered recombinant desulfatohirudin (CGP 39393) in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Comparative safety profiles of hirulog and heparin in patients undergoing coronary angioplasty. The Hirulog Angioplasty Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

Thrombin-specific inhibition by and slow cleavage of hirulog-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900660-2

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(98)00660-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9809887%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference